Aspen Pharmacare Bets on Manufacturing Rebound and Generic Semaglutide

South Africa’s largest listed drugmaker, Aspen Pharmacare, closed its 2026 financial year with flat sales and 22% growth in normalised headline earnings, then set out a two-part growth plan for 2027 built on a manufacturing rebound and an Aspen generic semaglutide rollout across selected emerging markets.

Group revenue was broadly flat at R34.9 billion. Normalised headline earnings per share (NHEPS) from continuing operations rose 22% at reported rates and 28% in constant currency to 801.5 cents. The balance sheet also swung from leveraged to net cash after the Asia-Pacific (APAC) disposal closed on 31 May 2026, which brought in about R28 billion of gross proceeds.

Headline numbers

Source: Aspen Pharmacare reviewed condensed Group financial results, 2 September 2026 (JSE SENS).

Ad

A cleaner earnings story

The earnings beat came while revenue stood still. Gross margin slipped 170 basis points to 40.3%, but the normalised EBITDA margin widened 240 basis points to 22.1% as costs fell. Reported operating profit swung to a R763 million gain from a R790 million loss a year earlier, a move distorted by large non-cash impairments and restructuring charges. Management and the market focus on normalised EBITDA and NHEPS instead.

Free cash flow recovered to about R3.8 billion from R166 million, helped by operating cash conversion above 100%, a working-capital ratio down to 44% from 47%, and a cut in capital expenditure to R3 billion from R5 billion. The APAC disposal generated a R2.4 billion profit on sale, at a multiple management put at 11.5 times EBITDA. After R0.5 billion of share buybacks, the group ended the year with roughly R0.8 billion of net cash. The dividend rose 10% to 232 cents per share, payable to shareholders on the register on 9 September 2026.

Manufacturing rebound

Management is selling manufacturing as the main 2027 engine. Group CEO Stephen Saad told Reuters the forecast more-than-doubling in manufacturing core profit reflects higher volumes at South African plants, partly from human insulin, plus higher volumes and a broader product mix at the French sterile operation.

Manufacturing revenue fell 10% in constant currency to R9.47 billion after the loss of an mRNA contract, yet normalised EBITDA still rose 21% to R828 million. Saad said the sterile finished-dose reshape in Gqeberha and France more than offset roughly R1 billion of EBITDA lost with that contract. Human-insulin contract manufacture won South African Health Products Regulatory Authority approval and began commercialisation in May 2026.

“Once we know we’ve got a product and it works, and we know it takes volumes, then we would consider moving (production) to our facility,” Saad told Reuters.

Aspen generic semaglutide and the GLP-1 push

Two GLP-1 positions now sit inside Commercial Pharmaceuticals. Mounjaro (tirzepatide), which Aspen distributes in South Africa for Eli Lilly, is already the local GLP-1 leader. Saad told Reuters the South African GLP-1 market has grown to nearly R3 billion, with Mounjaro holding more than half of sales, put at 53% on the investor call and up from about 15% at an earlier launch stage.

Aspen’s own generic semaglutide, the active ingredient in Novo Nordisk‘s Ozempic, is the second position. Health Canada has approved Aspen’s generic semaglutide injectable, with commercial timing tied to API supply from Dr. Reddy’s Laboratories. Saad named South Africa, parts of Latin America including Brazil, and the Middle East as first-wave markets, subject to regulatory approvals. The pricing thesis is explicit: generic semaglutide at less than half the originator price, aimed at expanding the treated population and shifting patients off unregistered compounded product. In-house manufacture is a later option, not the launch plan.

Where the growth is coming from

Commercial Pharmaceuticals remains the earnings engine, with a 27.1% normalised EBITDA margin against 8.7% in Manufacturing. Its revenue rose 5% in constant currency to R25.4 billion, split across Prescription (R9.07 billion), OTC (R7.16 billion) and Injectables (R9.18 billion).

Africa Middle East was the standout region, up 11% to R11.7 billion. Europe CIS, still the largest pool at R13.5 billion, fell 8%. China dropped 12% to R2.8 billion on planned discontinuations; stripping those out, commercial growth would have been closer to 7% in constant currency. The Americas were broadly flat.

FY2027 guidance and the risks

Group normalised EBITDA is guided to at least R9.0 billion in constant currency, against R7.7 billion in FY2026. NHEPS is guided to “substantial double-digit” growth, with some investor-call summaries putting it above 50% once the EBITDA lift and about R1.2 billion of net interest savings from the debt-free balance sheet are combined. Sterile finished-dose EBITDA is targeted at R2.2 billion, raised by R0.5 billion, and Mounjaro sales in South Africa are expected to exceed R2 billion.

The risks are real. Generic semaglutide launches are approval-gated: Canada is approved but constrained by API supply, while Brazil, South Africa, Kenya, Nigeria and the Middle East are not yet revenue lines. The mRNA contract left a R1 billion hole that insulin and new sterile clients must keep filling. A strong rand has already diluted reported growth, and Europe CIS and China remain soft. Impairments and restructuring still sit between reported and normalised earnings.

What it means for payers

For South African and sub-Saharan payers, a private-market GLP-1 category that has gone from niche to a multi-billion-rand line item raises familiar access questions: medical-scheme formularies, the point at which public diabetes programmes can afford any GLP-1, the interchangeability and quality of incoming generics, and the risk that compounded or unregistered product fills the gap. Aspen’s dual role as Lilly distributor today and generic manufacturer tomorrow will be watched by schemes and by SAHPRA.

The 2 September numbers give the two-bet story a credible base. They do not yet prove the R9 billion EBITDA outcome, the semaglutide launches, or the conversion of South Africa’s private GLP-1 boom into a broader African access franchise.

Sources: Aspen Pharmacare reviewed condensed Group financial results and SENS announcement (2 September 2026); Nqobile Dludla, “Aspen bets on manufacturing rebound, obesity drug push for growth“, Reuters (2 September 2026); Aspen FY2026 annual results presentation (3 September 2026).